



Nordic Market Update

Management can confirm that the projected **+11 MSEK in Nordic turnover for Q1** is well within reach, representing the highest quarterly sales to date in the region. Furthermore, the December tender in Sweden for the new products **Amlodipine** and **Imatinib** was successfully secured.

Over the next four months, we plan to launch **Atorvastatin**, **Darunavir** as well as additional strengths of **Amlodipine** and **Sertraline**. In addition to the established products above we will proceed to launch **Pazopanib** and **Dimethyl Fumarate** as soon as regulatory exclusivities and patents allow us.

The company has optimized its leadership structure, generating measurable cost savings while maintaining strong execution capabilities across the Nordic region. Despite the inherent volatility of monthly tenders, Newbury's remains well positioned for continued growth.

Leadership Update: Fredrik Hellqvist promoted to GM Nordic

To support the next phase of regional expansion, Fredrik Hellqvist has been promoted from VP Sales & Marketing to General Manager Nordic. Fredrik, who has been with Newbury Pharmaceuticals since 2021, will assume responsibility for the company's operations in the Nordic region. His leadership and deep market expertise will be central as the product portfolio and tender activity accelerate.

For more information, contact:

Karl Karlsson, CEO
karl.karlsson@newburypharma.com
Mobile: +46 46 12 11 20

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release
18 November 2025 13:50:00 CET



Attachments

[Nordic Market Update](#)